ArticleTranslational pediatrics2025
A predictive model for low bone mass in pediatric and adolescent patients with transfusion-dependent beta-thalassemia.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with transfusion-dependent beta-thalassemia (TDT) frequently experience osteoporosis, and low bone mass (LBM) is particularly common. However, there is no accurate predictive model for LBM risk in the pediatric and adolescent TDT cohort. This study aimed to create a predictive model to assess LBM risk in this specific population. Methods: Retrospective demographic and laboratory data of pediatric TDT patients were analyzed. The dataset was divided into training and test sets at an 8:2 ratio. Independent predictors of LBM were identified through logistic regression analysis and subsequently incorporated into six machine learning models to develop risk prediction models. Cross-validation was employed to evaluate the models' generalizability, while the test set was used to assess the effectiveness of the final optimal model. The predictive performance of the models was evaluated using receiver operating characteristic curves, calibration curves, and decision curve analysis. Results: A total of 389 TDT patients were analyzed, and age, insulin-like growth factor 1 (IGF-1) below -2 standard deviation (-2SD), and hypogonadism were identified as predictors of LBM. The Gaussian Naive Bayes (NB) model was optimal, showing areas under the curve (AUCs) of 0.732, 0.734, and 0.730 in training, validation, and test sets, respectively. An online tool was developed to calculate the precise probability of LBM in this population. Conclusions: We develop and validate a risk prediction model for LBM in pediatric and adolescent TDT patients, which facilitates the efficient identification of high-risk individuals in clinical practice and enables early intervention to prevent disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.